A Novel Monthly Dosing Regimen of Risedronate for the Treatment of Postmenopausal Osteoporosis: 2-Year Data

This 2-year trial evaluated the efficacy and tolerability of a monthly oral regimen of risedronate. Postmenopausal women with osteoporosis were randomly assigned to double-blind treatment with risedronate 75 mg on 2 consecutive days each month (2CDM) or 5 mg daily. The primary end point was the perc...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: McClung, Michael R., Benhamou, Claude-Laurent, Man, Zulema, Tlustochowicz, Witold, Zanchetta, Jose R., Eusebio, Rachelle, Balske, Ana M., Matzkin, Ellen, Olszynski, Wojciech P., Recker, Robert, Delmas, Pierre D.
Format: Artigo
Jezik:Inglês
Izdano: Springer-Verlag 2012
Teme:
Original Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3528955/
https://ncbi.nlm.nih.gov/pubmed/23150144
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00223-012-9668-4
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items